MACROGENICS INC
NASDAQ: MGNX (MacroGenics, Inc.)
Kemas kini terakhir: 3 jam lalu4.32
0.28 (6.93%)
| Penutupan Terdahulu | 4.04 |
| Jumlah Dagangan | 581,566 |
| Harga / Jualan (P/S) | 1.46 |
| Harga / Buku (P/B) | 6.00 |
| Julat 52 Minggu |
| Margin Keuntungan | -36.23% |
| Margin Operasi (TTM) | -323.11% |
| EPS Cair (TTM) | -0.880 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 44.90% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 220.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 47.35% |
| Nisbah Semasa (MRQ) | 3.28 |
| Aliran Tunai Operasi (OCF TTM) | -69.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -40.45 M |
| Pulangan Atas Aset (ROA TTM) | -26.29% |
| Pulangan Atas Ekuiti (ROE TTM) | -60.25% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | MacroGenics, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.44 |
|
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 3.01% |
| % Dimiliki oleh Institusi | 73.84% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| PETERS JEFFREY STUART | - | 4.17 | -31,105 | -129,708 |
| Jumlah Keseluruhan Kuantiti Bersih | -31,105 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -129,708 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 4.17 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PETERS JEFFREY STUART | Pegawai | 19 Aug 2026 | Jual automatik (-) | 31,105 | 4.17 | 129,708 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |